Suzhou Pharma Services

Belkins
Suzhou Pharma Services, a division of Amerigen Pharmaceuticals, is a contract development and manufacturing organization focused on oral solid dose forms. With US offices located in East Brunswick, NJ and the primary manufacturing site located in Suzhou, China, we are licensed by the Chinese sFDA and the US FDA. The management team in China and the USA is comprised of highly experienced, Western trained leaders, averaging 20+ years experience with multi-national branded and generic pharmaceutical companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

HOW AI IS HELPING PHARMA COPE WITH SUPPLY CHAIN DISRUPTION

EPM Magazine | June 25, 2020

news image

As the Covid-19 crisis continues to unsettle global economies and business sectors worldwide, pharma companies are facing huge disruption to their supply chains and clinical research. And while research into potential Covid-19 vaccines and treatments is speeding along, the pandemic has slowed or brought to a halt clinical trials for other diseases, with organisations like Eli Lilly and other big name pharma’s’ putting the brakes on non Covid-19 trial activity. In fact,...

Read More

PHARMA TECH

MERCK DRIVES NEW INNOVATION & ADDS CAPACITY TO ADVANCE NEXT GENERATION ANTIBODY-DRUG CONJUGATE (ADC) THERAPIES

Merck | October 29, 2021

news image

Merck, a leading science and technology company, today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies. These initiatives underscore Merck's continued investment in novel modalities and support the company's efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. "ADCs have experienced remarkable growth, with commerci...

Read More

DECK 7 OPTIMIZES ITS STRATEGIC MARKETING FOR 2020 USING A REVISED ABM STRATEGY

DECK 7 | February 04, 2020

news image

Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...

Read More

RESEARCH

REGENERON, FOLLOWING IN LILLY'S FOOTSTEPS, WINS FDA EMERGENCY NOD FOR COVID-19 ANTIBODY COCKTAIL

Regeneron | November 24, 2020

news image

Covid-19 Regeneron antibody cocktail, one of the drugs of President Donald Trump was given after he was infected with the SARS-COV-02 virus, had been cleaned for emergency use by the FDA. And, despite the towering vaccine slide, one analyst still sees therapy as a $ 1 billion-plus business. Authorization of Emergency Use (EUA) for Regn-COV2, a combination of monoclonal antibodies Kasarivimab and IMdevimab, marked the second for antibody therapy. The first to go to Bamlanivimab Eli...

Read More

EPM Magazine | June 25, 2020

news image

HOW AI IS HELPING PHARMA COPE WITH SUPPLY CHAIN DISRUPTION

As the Covid-19 crisis continues to unsettle global economies and business sectors worldwide, pharma companies are facing huge disruption to their supply chains and clinical research. And while research into potential Covid-19 vaccines and treatments is speeding along, the pandemic has slowed or brought to a halt clinical trials for other diseases, with organisations like Eli Lilly and other big name pharma’s’ putting the brakes on non Covid-19 trial activity. In fact,...

Read More

PHARMA TECH

Merck | October 29, 2021

news image

MERCK DRIVES NEW INNOVATION & ADDS CAPACITY TO ADVANCE NEXT GENERATION ANTIBODY-DRUG CONJUGATE (ADC) THERAPIES

Merck, a leading science and technology company, today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies. These initiatives underscore Merck's continued investment in novel modalities and support the company's efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. "ADCs have experienced remarkable growth, with commerci...

Read More

DECK 7 | February 04, 2020

news image

DECK 7 OPTIMIZES ITS STRATEGIC MARKETING FOR 2020 USING A REVISED ABM STRATEGY

Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...

Read More

RESEARCH

Regeneron | November 24, 2020

news image

REGENERON, FOLLOWING IN LILLY'S FOOTSTEPS, WINS FDA EMERGENCY NOD FOR COVID-19 ANTIBODY COCKTAIL

Covid-19 Regeneron antibody cocktail, one of the drugs of President Donald Trump was given after he was infected with the SARS-COV-02 virus, had been cleaned for emergency use by the FDA. And, despite the towering vaccine slide, one analyst still sees therapy as a $ 1 billion-plus business. Authorization of Emergency Use (EUA) for Regn-COV2, a combination of monoclonal antibodies Kasarivimab and IMdevimab, marked the second for antibody therapy. The first to go to Bamlanivimab Eli...

Read More